Esmethadone hydrochloride is under clinical development by Relmada Therapeutics and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Esmethadone hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Esmethadone hydrochloride overview

REL-1017 (D-methadone) is under development for the treatment of major depressive disorder, treatment resistant depression. The drug candidate is administered through oral route as a solution and tablet. The drug candidate is a nonopioid analgesic which acts by targeting N-methyl-D-aspartate (NMDA) receptor. It is a d optical isomer of racemic methadone. It is a new chemical entity.

It was also under development for the treatment of post herpetic neuralgia, Rett syndrome, ophthalmology, mitochondrial diseases, amyotrophic lateral sclerosis, substance (drug) abuse and neuropathic pain and restless leg syndrome.

Relmada Therapeutics overview

Relmada Therapeutics, formerly Camp Nine, is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product esmethadone is used for the treatment of central nervous system (CNS) diseases and other disorders. It conducts various phases of clinical trials like Phase I and II. The company also carries out research and development. Relmada Therapeutics is headquartered in Coral Gables, Florida, the US.

For a complete picture of Esmethadone hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.